Small,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 15, 2024
Abstract
The
treatment
of
brain
diseases
has
always
been
the
focus
attention.
Due
to
presence
blood‐brain
barrier
(BBB),
most
small
molecule
drugs
are
difficult
reach
brain,
leading
undesirable
therapeutic
outcomes.
Recently,
nanomedicines
that
can
cross
BBB
and
precisely
target
lesion
sites
have
emerged
as
thrilling
tools
enhance
early
diagnosis
treat
various
intractable
disorders.
Extensive
research
shown
reactive
oxygen
species
(ROS)
play
a
crucial
role
in
occurrence
progression
diseases,
including
tumors
neurodegenerative
(NDDs)
such
Alzheimer's
disease,
Parkinson's
stroke,
or
traumatic
injury,
making
ROS
potential
target.
In
this
review,
on
structure
function
well
mechanisms
first
elaborated
through
which
nanomedicine
traverses
it.
Then,
recent
studies
production
summarized
photodynamic
therapy
(PDT),
chemodynamic
(CDT),
sonodynamic
(SDT)
for
treating
tumors,
depletion
NDDs.
This
provides
valuable
guidance
future
design
ROS‐targeted
disease
treatment.
ongoing
challenges
perspectives
developing
nanomedicine‐based
management
also
discussed
outlined.
Nanoscale Advances,
Journal Year:
2024,
Volume and Issue:
6(9), P. 2270 - 2286
Published: Jan. 1, 2024
Breast
cancer
is
a
global
health
challenge
with
staggering
statistics
underscoring
its
pervasive
impact.
The
burden
of
this
disease
measured
in
terms
prevalence
and
the
challenges
it
poses
to
healthcare
systems,
necessitating
closer
look
at
epidemiology
Current
breast
treatments,
including
surgery,
chemotherapy,
radiation
therapy,
targeted
therapies,
have
made
significant
strides
improving
patient
outcomes.
However,
they
are
not
without
limitations,
often
leading
adverse
effects
development
drug
resistance.
This
comprehensive
review
delves
into
complex
landscape
cancer,
incidence,
current
treatment
modalities,
inherent
limitations
existing
therapeutic
approaches.
It
also
sheds
light
on
promising
role
nanotechnology,
encompassing
both
inorganic
organic
nanoparticles
equipped
ability
selectively
deliver
agents
tumor
sites,
battle
against
cancer.
addresses
emerging
their
associated
challenges,
future
prospects
delivery
management.
Molecular Cancer,
Journal Year:
2025,
Volume and Issue:
24(1)
Published: March 4, 2025
Among
the
emerging
strategies
for
cancer
theranostics,
nanomedicines
offer
significant
promise
in
advancing
both
patients'
diagnosis
and
treatment.
In
combination
with
nanobodies,
can
potentially
enhance
precision
efficiency
of
drug
or
imaging
agent
delivery,
addressing
key
limitations
current
approaches,
such
as
off-target
toxicities.
The
development
will
be
further
accelerated
by
creation
smart
nanoparticles,
their
integration
immunotherapy.
Obviously,
success
nano-immunotherapy
depend
on
a
comprehensive
understanding
tumor
microenvironment,
including
complex
interplay
mechanisms
that
drive
cancer-mediated
immunosuppression
immune
escape.
Hence,
effective
therapeutic
targeting
microenvironment
requires
modulation
cell
function,
overcoming
resistance
associated
stromal
components
extracellular
matrix,
and/or
direct
elimination
cells.
Identifying
molecules
involved
progression
is,
therefore,
essential
developing
therapies
diagnostic
tools
predict
patient
responses
to
treatment
monitor
outcomes.
Current
are
being
designed
careful
consideration
factors
choice
carrier
(e.g.,
biocompatibility,
controlled
cargo
release)
moiety.
unique
properties
nanobodies
make
them
an
engineering
tool
target
biological
high
affinity
specificity.
this
review,
we
focus
latest
applications
various
purposes.
We
also
explore
main
types
nanoparticles
used
immunotherapies,
well
formulating
nanoparticle-nanobody
conjugates.
Finally,
highlight
how
nanobody-nanoparticle
formulations
nanomedicines.
Deleted Journal,
Journal Year:
2024,
Volume and Issue:
32(2), P. 200809 - 200809
Published: April 29, 2024
Oncolytic
virotherapy
represents
a
promising
approach
in
cancer
immunotherapy.
The
primary
delivery
method
for
oncolytic
viruses
(OVs)
is
intratumoral
injection,
which
apparently
limits
their
clinical
application.
For
patients
with
advanced
disseminated
metastasis,
systemic
administration
considered
the
optimal
approach.
However,
direct
of
naked
through
intravenous
injection
presents
challenges,
including
rapid
clearance
by
immune
system,
inadequate
accumulation
tumors,
and
significant
side
effects.
Consequently,
development
drug
strategies
has
led
to
emergence
various
bio-materials
serving
as
viral
vectors,
thereby
improving
anti-tumor
efficacy
virotherapy.
This
review
provides
an
overview
innovative
delivering
OVs,
focus
on
nanoparticle-based
or
cell-based
systems.
Recent
pre-clinical
studies
are
examined
highlight
enhanced
using
these
novel
platforms.
In
addition,
prevalent
challenges
current
research
briefly
discussed,
potential
solutions
proposed.
Pharmaceutics,
Journal Year:
2025,
Volume and Issue:
17(2), P. 205 - 205
Published: Feb. 6, 2025
Cancer
represents
a
significant
societal,
public
health,
and
economic
challenge.
Conventional
chemotherapy
is
based
on
systemic
administration;
however,
it
has
current
limitations,
including
poor
bioavailability,
high-dose
requirements,
adverse
side
effects,
low
therapeutic
indices,
the
development
of
multiple
drug
resistance.
These
factors
underscore
need
for
innovative
strategies
to
enhance
delivery
directly
tumours.
However,
local
treatment
also
presents
challenges,
penetration
through
endothelial
layers,
tissue
density
in
tumour
microenvironment,
interstitial
fluid
pressure,
physiological
conditions
within
tumour,
permanence
at
site
action.
Nanotechnology
promising
alternative
addressing
these
challenges.
This
narrative
review
elucidates
potential
nanostructured
formulations
cancer
treatment,
providing
illustrative
examples
an
analysis
advantages
challenges
associated
with
this
approach.
Among
nanoformulations
developed
breast,
bladder,
colorectal,
oral,
melanoma
cancer,
polymeric
nanoparticles,
liposomes,
lipid
nanohydrogels
have
demonstrated
particular
efficacy.
systems
permit
mucoadhesion
enhanced
penetration,
thereby
increasing
concentration
(bioavailability)
consequently
improving
anti-tumour
efficacy
potentially
reducing
effects.
In
addition
studies
indicating
chemotherapy,
nanocarriers
can
be
used
as
theranostic
approach
combination
irradiation
methods.
